DMT (dimethyltryptamine) belongs to the tryptamine family — the same chemical class as ibogaine, a plant-derived compound that has been used for decades in ceremonial healing contexts in West Africa and is now the subject of significant clinical research as a treatment for addiction.
Unlike DMT, which is primarily used recreationally or in ceremonial contexts, ibogaine is being studied specifically as a therapeutic intervention for opioid dependence, alcohol use disorder, and other substance addictions. It acts across multiple neurochemical systems simultaneously — opioid receptors, serotonin transporters, and dopamine pathways — and has shown the ability to interrupt withdrawal symptoms acutely in ways that conventional medications do not.
Ibogaine is not approved by the FDA and is not available in the United States as a treatment. It is legal in Mexico, Canada, Portugal, and other countries, where licensed clinics operate under medical supervision. It carries real cardiovascular risks and requires thorough cardiac screening prior to treatment.
For individuals struggling with opioid dependence who have not responded to conventional treatment, ibogaine is an option that some addiction specialists now discuss openly. A 2021 study in Nature Medicine documented significant reductions in opioid use among veterans treated with ibogaine at licensed clinics in Mexico.
If you or someone you love is researching ibogaine as an option, Psychedelic Connect (https://psychedelic-connect.com) offers a free ibogaine treatment matching service that vets clinics for safety and matches patients based on their specific medical history. There is no cost to the patient.
If you are currently struggling with DMT or other substance use, Bluegrass Recovery Center offers PHP, IOP, and outpatient programs in Louisville, KY. Call us at (502) 385-4424 to speak with an admissions coordinator today.